1.
|
Ochiai T, Nishimura K, Noguchi H, Kitajima
M, Tsuruoka Y and Takahashi Y: Evaluation of 5-fluorouracil
applicability by multi-point collagen gel droplet embedded drug
sensitivity test. Oncol Rep. 14:201–205. 2005.PubMed/NCBI
|
2.
|
Ochiai T, Nishimura K, Noguchi H, et al:
Evaluation of 5-fluorouracil applicability by the collagen gel
droplet embedded drug sensitivity test with area under the curve
analysis. Anticancer Drugs. 18:17–21. 2007. View Article : Google Scholar : PubMed/NCBI
|
3.
|
Kobayashi H, Tanisaka K, Doi O, et al: An
in vitro chemosensitivity test for soid human tumors using
collagen gel droplet embedded cultures. Int J Oncol. 11:449–455.
1997.
|
4.
|
Kobayashi H, Higashiyama M, Minamigawa K,
et al: Examination of in vitro chemosensitivity test using collagen
droplet culture method with colorimetric endpoint quantification.
Jpn J Cancer Res. 92:203–210. 2001. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Tournigand C, André T, Achille E, et al:
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: a randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
6.
|
Falcone A, Ricci S, Brunetti I, et al:
Gruppo Oncologico Nord Ovest. Phase III trial of infusional
fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI)
compared with infusional fluorouracil, leucovorin and irinotecan
(FOLFIRI) as first-line treatment for metastatic colorectal cancer:
the Gruppo Oncologico Nord Ovest. J Clin Oncol. 25:1670–1676.
2007.
|
7.
|
Saltz LB, Clarke S, Díaz-Rubio E, et al:
Bevacizumab in combination with oxaliplatin-based chemotherapy as
first-line therapy in metastatic colorectal cancer: a randomized
phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
|
8.
|
Kabbinavar FF, Hambleton J, Mass RD, et
al: Combined analysis of efficacy: the addition of bevacizumab to
fluorouracil/leucovorin improves survival for patients with
metastatic colorectal cancer. J Clin Oncol. 23:3706–3712. 2005.
View Article : Google Scholar : PubMed/NCBI
|
9.
|
André T, Louvet C, Maindrault-Goebel F, et
al: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin
and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for
pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer.
35:1343–1347. 1999.PubMed/NCBI
|
10.
|
Maindrault-Goebel F, Louvet C, André T, et
al: Oxaliplatin added to the simplified bimonthly leucovorin and
5-fluorouracil regimen as second-line therapy for metastatic
colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer. 35:1338–1342.
1999. View Article : Google Scholar
|
11.
|
Grothey A, Sargent D, Goldberg RM, et al:
Survival of patients with advanced colorectal cancer improves with
the availability of fluorouracil-leucovorin, irinotecan and
oxaliplatin in the course of treatment. J Clin Oncol. 22:1209–1214.
2004. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Matsuo A, Watanabe A, Takahashi T, et al:
A simple method for classification of cell death by use of thin
layer collagen gel for the detection of apoptosis and/or necrosis
after cancer chemotherapy. Jpn J Cancer Res. 92:813–819. 2001.
View Article : Google Scholar : PubMed/NCBI
|
13.
|
Kobayashi H: Development of a new in vitro
chemosensitivity test using collagen gel droplet culture and image
analysis for clinical usefulness. Recent Results Cancer Res.
161:48–61. 2003. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Ochiai T, Nishimura K, Noguchi H, et al:
Prognotic impact of orotate phosphoribosyl transferase among
5-fluorouracil metabolic enzymes in resectable colorectal cancers
treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int J
Cancer. 118:3084–3088. 2006. View Article : Google Scholar
|
15.
|
Minderman H, Conroy JM, O'Loughlin KL, et
al: In vitro and in vivo irinotecan-induced changes in expression
profiles of cell cycle and apoptosis-associated genes in acute
myeloid leukemia cells. Mol Cancer Ther. 4:885–900. 2005.
View Article : Google Scholar : PubMed/NCBI
|
16.
|
Lévi F, Metzger G, Massari C, et al:
Oxaliplatin: pharmacokinetics and chronopharmacological aspects.
Clin Pharmacokinet. 38:1–21. 2000.
|
17.
|
Guichard S, Hennebelle I, Bugat R, et al:
Cellular interactions of 5-fluorouracil and the camptothecin
analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell
line. Biochem Pharmacol. 55:667–676. 1998. View Article : Google Scholar : PubMed/NCBI
|
18.
|
Pavillard V, Formento P, Rostagno O, et
al: Combination of irinotecan (CPT-11) and 5-fluorouracil with an
analysis of cellular determinants of drug activity. Biochem
Pharmacol. 56:1315–1322. 1998. View Article : Google Scholar : PubMed/NCBI
|
19.
|
Banerjee D, Schnieders B, Fu JZ, Adhikari
D, Zhao SC and Bertino JR: Role of E2F-1 in chemosensitivity.
Cancer Res. 58:4292–4296. 1998.PubMed/NCBI
|
20.
|
Fukushima M, Uchida J, Sakamoto K, Ohshima
H and Taguchi T: Molecular mechanism of down-regulation by CPT-11
of thymidylate synthase highly expressing in gastrointestinal
cancer xenografts during combined treatment with fluoropyrimidines.
Eur J Cancer. 1:S622003. View Article : Google Scholar
|
21.
|
Ichikawa W, Takahashi T, Suto K, et al:
Thymidylate synthase predictive power is overcome by irinotecan
combination therapy with S-1 for gastric cancer. Br J Cancer.
91:1245–1250. 2004. View Article : Google Scholar : PubMed/NCBI
|
22.
|
Fukushima M: S-1 review from preclinical
pharmacology. Gastric Cancer. 12:3–9. 2009. View Article : Google Scholar
|